PPA
ATRA icon

Parametric Portfolio Associates’s Atara Biotherapeutics ATRA Stock Holding History

Parametric Portfolio Associates’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$295K Sell
1,269
-951
-43% -$303K ﹤0.01% 3286
2021
Q4 		$875K Buy
2,220
+326
+17% +$137K ﹤0.01% 2838
2021
Q3 		$848K Sell
1,894
-427
-18% -$153K ﹤0.01% 2872
2021
Q2 		$902K Sell
2,321
-275
-11% -$98.1K ﹤0.01% 2818
2021
Q1 		$932K Buy
2,596
+608
+31% +$269K ﹤0.01% 3195
2020
Q4 		$976K Buy
1,988
+238
+14% +$110K ﹤0.01% 3068
2020
Q3 		$567K Buy
1,750
+264
+18% +$89.9K ﹤0.01% 3210
2020
Q2 		$541K Buy
1,486
+193
+15% +$48.8K ﹤0.01% 3233
2020
Q1 		$275K Sell
1,293
-67
-5% -$21.3K ﹤0.01% 3426
2019
Q4 		$560K Buy
1,360
+285
+27% +$98.3K ﹤0.01% 3327
2019
Q3 		$380K Buy
+1,075
New +$401K ﹤0.01% 3438
2019
Q2 		– Sell
-384
Closed -$382K – 3958
2019
Q1 		$382K Sell
384
-705
-65% -$655K ﹤0.01% 3459
2018
Q4 		$945K Sell
1,089
-22
-2% -$20.4K ﹤0.01% 3014
2018
Q3 		$1.15M Sell
1,111
-1
-0.1% -$978 ﹤0.01% 3014
2018
Q2 		$1.02M Buy
1,112
+27
+2% +$29K ﹤0.01% 3049
2018
Q1 		$1.06M Sell
1,085
-627
-37% -$571K ﹤0.01% 2983
2017
Q4 		$775K Buy
1,712
+474
+38% +$175K ﹤0.01% 3137
2017
Q3 		$512K Buy
1,238
+51
+4% +$19.2K ﹤0.01% 3410
2017
Q2 		$415K Buy
1,187
+171
+17% +$65.9K ﹤0.01% 3471
2017
Q1 		$522K Buy
1,016
+391
+63% +$162K ﹤0.01% 3188
2016
Q4 		$222K Sell
625
-88
-12% -$37.3K ﹤0.01% 3553
2016
Q3 		$381K Buy
713
+84
+13% +$45.6K ﹤0.01% 3303
2016
Q2 		$354K Buy
+629
New +$302K ﹤0.01% 3378

Other funds holding ATRA

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Parametric Portfolio Associates's ATRA Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Atara Biotherapeutics (ATRA) stake by 43% in Q1 2022, selling an estimated $303K and leaving 1,269 shares worth $295K. The position accounts for ﹤0.01% of the portfolio, ranked #3286.

Parametric Portfolio Associates first reported a position in ATRA in Q2 2016 and has held it in 23 quarters since. The position peaked at $1.15M in Q3 2018. 144 funds tracked by Wall St. Rank hold ATRA as of Q1 2022.

  • Parametric Portfolio Associates held 1,269 shares of Atara Biotherapeutics worth $295K as of Q1 2022.
  • Parametric Portfolio Associates sold 951 Atara Biotherapeutics shares in Q1 2022, an estimated $303K.
  • Atara Biotherapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3286 holding.
  • Parametric Portfolio Associates first reported a position in Atara Biotherapeutics in Q2 2016 and has held it in 23 quarters since.
  • Parametric Portfolio Associates's Atara Biotherapeutics position peaked at $1.15M in Q3 2018.
  • 144 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.